ClinicalTrials.gg
RecruitingNCT07541833Updated Jun 26, 2026

Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)

An observational study in Cardiomyopathy, sponsored by Bristol-Myers Squibb. Recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Primary conditionCardiomyopathy, HypertrophicRegistry: CardiomyopathiesReclassifiedWhy we changed it
Registry
Cardiomyopathies — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cardiomyopathy, Hypertrophic
Why
  1. The study's title name Cardiomyopathy, Hypertrophic, a narrower term within Cardiomyopathies.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bristol-Myers Squibb · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
36
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 10 open to participants now, 15 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.

Planned enrollment
14th of 15
36 · median 200
Started
2026
with 4 others
Observational
15 of 32
9 open now
Primary completion
2026-12
later than 5 of 14 live
Registered
29th of 32
by date

Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 14th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2026, is one of 15 observational ones, reaches primary completion later than 5 of the 14 other live ones, and was the 29th registered.

Cardiomyopathy, Hypertrophic

365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

10 of the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in adults diagnosed with symptomatic obstructive hypertrophic cardiomyopathy (HOCM) receiving cibenzoline in Japan

03

Conditions studied

  • Cardiomyopathy

Browse trials for

Keywords

  • hypertrophic cardiomyopathy (HOCM)
04

In context

Cardiomyopathy, Hypertrophic Reclassified

365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.

This study's planned enrollment of 36 is below the median of 259 across 174 observational studies indexed under Cardiomyopathy, Hypertrophic.

Browse Cardiomyopathy, Hypertrophic studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within Cardiomyopathy, Hypertrophic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiomyopathies. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adults diagnosed with symptomatic obstructive hypertrophic cardiomyopathy (HOCM) who have been prescribed mavacamten treatment by the treating physician as part of routine clinical care, in Japan

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form (ICF): Participants, or their legally acceptable representative, must have signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved ICF in accordance with regulatory, local, and institutional guidelines. This must be obtained before the performance of any protocol-related procedures.
  • Diagnosed with obstructive hypertrophic cardiomyopathy (HOCM) consistent with Japanese Circulation Society guidelines (2025), i.e., satisfy all criteria below:

    • Has unexplained left ventricular (LV) hypertrophy with nondilated ventricular chambers in the absence of other cardiac (e.g., hypertension, aortic stenosis) or systemic disease and with maximal LV wall thickness ≥ 15 mm (or ≥ 13 mm with positive family history of HCM).
    • Has Left Ventricular Outflow Tract (LVOT) peak gradient ≥ 30 mmHg (resting, Valsalva maneuver, or post-exercise).
  • Has documented (LVEF) ≥ 55% at baseline.
  • Participants who meet any of the following criteria:

    • Participants who have previously received mavacamten continuously for ≥ 16 weeks
    • Participants who are currently receiving mavacamten
    • Participants who are scheduled to receive mavacamten
  • Treated with a stable dose of cibenzoline for at least 3 months prior to initiating mavacamten treatment. Tapered cibenzoline within 3 months prior to initiating mavacamten treatment is allowed if stable dose of cibenzoline was used for at least 3 months prior to tapering.
  • At least 18 years of age at the time of signing the informed consent.

Exclusion criteria

Exclusion Criteria:

  • to the active substance or to any of the .
  • During pregnancy and in women of .
  • Treated with strong inhibitors (itraconazole, clarithromycin, voriconazole, posaconazole, ritonavir, cobicistat, ceritinib, ensitrelvir fumaric acid, lonafarnib, josamycin, or mifepristone/misoprostol).
  • Severe hepatic impairment ( C).
  • Severe atrioventricular block or severe sinoatrial block.
  • Congestive heart failure.
  • Requiring dialysis.
  • Angle-closure glaucoma.
  • Tendency to urinary retention.
  • Treated with vardenafil hydrochloride hydrate, moxifloxacin hydrochloride, lascufloxacin hydrochloride (injection), toremifene citrate, fingolimod hydrochloride, siponimod fumarate, or eliglustat tartrate.
  • Mavacamten treatment within 8 weeks prior to baseline. Mavacamten treatment initiation was judged based on post-exercise LVOT peak gradient.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

06

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
36 participants (estimated)
Patient registry
No

Groups and cohorts

  • Switch Group

    Participants who discontinue cibenzoline before or at the initiation of mavacamten treatment

    Drug: Mavacamten

  • Tapering/Add-on Group

    Participants who continue cibenzoline at the initiation of mavacamten treatment

    Drug: Mavacamten

Interventions

07

What researchers measure

Primary outcomes

  1. Change in either resting or Valsalva Left Ventricular Outflow Tract (LVOT) peak gradient whichever used to judge the initiation of mavacamten treatment

    Time frame: Baseline and up to week 16

Secondary outcomes

  1. Change in Left Ventricular Outflow Tract (LVOT) peak gradient (resting and Valsalva maneuver)

    Time frame: Baseline and up to week 16

  2. Proportion of patients achieving target Left Ventricular Outflow Tract (LVOT) peak gradients (<50 mmHg / <30 mmHg) (Valsalva maneuver or post-exercise)

    Time frame: Baseline and up to week 16

  3. Proportion of patients with any decrease in resting or Valsalva Left Ventricular Outflow Tract (LVOT) peak gradients

    Time frame: Baseline and up to week 16

  4. Proportion of patients with ≥1 New York Heart Association (NYHA) functional class improvement

    Time frame: Baseline and up to week 16

  5. Change in cardiac biomarkers from baseline

    Biomarkers include brain natriuretic peptide (BNP) or N-terminal prohormone of BNP (NT-proBNP)

    Time frame: Baseline and up to week 16

  6. Change in systolic function parameters (left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) from baseline assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  7. Number of participants with Left Ventricular Ejection Fraction (LVEF) <50% as assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  8. Change in left ventricular cardiac output (LVCO) from baseline assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  9. Change in early diastolic mitral annular velocity (e') measured at the lateral, septal, and averaged positions from baseline assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  10. Change in E/e' ratio measured at the lateral, septal, and averaged positions and E/A ratio (ratio of early (E) to late (A) ventricular filling velocities) from baseline assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  11. Change in cardiac structural dimensions from baseline assessed by transthoracic echocardiography (TTE)

    Structural dimensions include: septal thickness, posterior wall thickness, maximal left ventricular wall thickness, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, and left atrial dimension

    Time frame: Baseline and up to week 16

  12. Change in left ventricular outflow tract (LVOT) gradient measured at rest and during Valsalva maneuver from baseline assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  13. Change in cardiac chamber volumes (left ventricular end-diastolic volume, left ventricular end-systolic volume, and left atrial volume) from baseline assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  14. Change in indexed cardiac chamber volumes (left ventricular end-diastolic volume index, left ventricular end-systolic volume index, and left atrial volume index) from baseline assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  15. Change in left ventricular diameters (left ventricular end-diastolic diameter and left ventricular end-systolic diameter) from baseline assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  16. Change in indexed left ventricular diameters (left ventricular end-diastolic diameter index and left ventricular end-systolic diameter index) from baseline assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  17. Change in left atrial dimension from baseline assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  18. Change in left ventricular mass index (LVMI) from baseline assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  19. Number of participants with systolic anterior motion (SAM) of the mitral valve, and number of participants with mitral regurgitation (MR) assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  20. Number of treatment emergent adverse events (TEAEs)/adverse drug reactions (ADRs) and serious TEAEs/ADRs

    Time frame: Up to week 16

  21. Proportion of participants continuing cibenzoline

    Time frame: Baseline and weeks 4, 8, 12, and 16

  22. Proportion of patients who decrease or increase dose and/or frequency of cibenzoline, beta blocker, or calcium channel blocker

    Time frame: Baseline and weeks 4, 8, 12, and 16

  23. Daily dose of cibenzoline, beta blocker, or calcium channel blocker

    Time frame: Baseline and weeks 4, 8, 12, and 16

  24. Change in Left Ventricular Ejection Fraction (LVEF) as assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

  25. Change in left ventricular stroke volume (LVSV) from baseline assessed by transthoracic echocardiography (TTE)

    Time frame: Baseline and up to week 16

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Apr 21, 2026
StartActual
Feb 5, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07541833
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Feb 5, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 26, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristo Myers Squibb
study director · Bristo Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion